A meeting of the National Drug Scheduling Advisory Committee (NDSAC) was held on June 5, 2022 with the following interim recommendations made:

• Diclofenac diethylamine – for human use – when sold as a single medicinal ingredient for topical use on the skin in concentrations greater than 1.16% and less than or equal to 2.32% for not more than 7 days – in package sizes containing greater than 2.6g of diclofenac diethylamine be granted Schedule III status
• Diclofenac diethylamine – for human use – when sold as a single medicinal ingredient for topical use on the skin in concentrations greater than 1.16% and less than or equal to 2.32% for not more than 7 days – in package sizes containing no more than 2.6g of diclofenac diethylamine be granted Unscheduled status
• Diclofenac diethylamine – for human use – when sold as a single medicinal ingredient for topical use on the skin in concentrations of not more than 1.16% for not more than 7 days remain Unscheduled

Any objections to these interim recommendations must be received by the NAPRA office by end of day July 13, 2022. Questions or comments should be directed to the NDSAC Secretariat via email at ndsac@napra.ca.